case_images: PMC11821504_01
case_images: Head MRI and chest CT in December, 2022.
case_images: fonc-15-1502934-g001.jpg
case_images: PMC11821504_01_fonc-15-1502934-g001.jpg
case_images: f1
case_images: Subsequent imaging studies revealed abnormal signals in the frontal, parietal, and occipital sulci of the cerebrum on head MRI, with widening noted in the right frontal lobe ( Figure 1 ). Figure 1 ). Further positron emission tomography-computed tomography (PET-CT) scan showed increased tracer uptake of multiple tumor nodules localized in the right lower lobe (SUVmax 6.0) and extensive metastasis (SUVmax 7.3) ( Supplementary Figure 1 ). We have documented changes in clinical manifestations, imaging exams, and genetic testing via next-generation sequencing (NGS) throughout the treatment process (see  Table 2 ,  Figure 3 ,  Supplementary Table 1 ).
case_images: Dynamic monitoring of CEA and cfDNA in the CSF and in the blood.
case_images: fonc-15-1502934-g002.jpg
case_images: PMC11821504_01_fonc-15-1502934-g002.jpg
case_images: f2
case_images: In terms of pathological diagnosis, atypical cells were only detected in CSF ( Supplementary Figure 2 ), but not in the right pleural effusion. Additionally, CEA levels in blood and CSF gradually normalized during follow-up ( Figure 2 ), and no atypical cells were found in CSF after repeated examinations. cfDNA concentration in CSF significantly decreased early in treatment but slowly increased at 3 months before decreasing again at 5 months. In contrast, cfDNA levels in blood gradually decreased over the first 6 months of treatment followed by a rebound at month 7 ( Figure 2 ).
case_images: The imaging results obtained from the continuous follow-up.
case_images: fonc-15-1502934-g003.jpg
case_images: PMC11821504_01_fonc-15-1502934-g003.jpg
case_images: f3
case_images: We have documented changes in clinical manifestations, imaging exams, and genetic testing via next-generation sequencing (NGS) throughout the treatment process (see  Table 2 ,  Figure 3 ,  Supplementary Table 1 ).